House Passes NDAA Amendments Codifying Trump's Psychedelics EO

Photo by RDNE Stock project via Pexels.

The House of Representatives passed the FY2027 National Defense Authorization Act, H.R. 8800, by a 216-212 vote on Wednesday, July 22, 2026 -- and tucked inside that sprawling defense package are two psychedelics provisions that got almost no floor debate but could reshape how the military handles PTSD and traumatic brain injury for years to come. Both measures cleared as part of an en bloc amendment package adopted by voice vote before the bill's final passage, the kind of procedural bundling that lets non-controversial items move without a recorded vote or much public attention.

Together, the amendments extend a Pentagon psychedelics research program that Biden signed into law in 2024 from three years to nine, pushing its expiration date all the way to September 30, 2033. They also codify pieces of an executive order President Trump signed in April 2026 on psychedelic medicine, giving that order's directives the weight of statute rather than leaving them dependent on the whims of whoever occupies the White House next. The underlying 2024 program already allows active-duty troops with PTSD or TBI to enroll in clinical trials of psilocybin, MDMA, ibogaine and 5-MeO-DMT. What the House just did is lock that door open for the better part of a decade. The bill now moves to conference with the Senate, where negotiators will have to reconcile it with that chamber's version of the NDAA -- and a separate, standalone bill to reschedule ibogaine is still working its way through the process alongside it.

What the House Actually Voted On

Photo by MotionStudios via Pixabay.

The vote itself was tight and almost entirely along party lines, 216-212, reflecting how contentious this year's defense authorization has become on unrelated funding and policy fights. But the psychedelics language sailed through without that friction. Before final passage, the House adopted a package of amendments en bloc -- a bundling mechanism leadership uses to move dozens of smaller, less controversial items at once, usually by voice vote rather than a recorded roll call. That's exactly what happened here.

Two separate amendments dealing with psychedelics rode inside that package. Amendment No. 184, sponsored by Rep. Morgan Luttrell of Texas, extends the timeline of the military's existing psychedelics research authority. Amendment No. 29, brought by Luttrell alongside Reps. Lou Correa, Michael Rulli and Michael McCaul, writes specific pieces of President Trump's April 2026 executive order on psychedelic medicine into the underlying defense statute. Neither amendment generated floor debate worth mentioning, which is fairly typical for provisions that already have bipartisan buy-in and don't touch the more politically charged parts of the bill.

With passage of H.R. 8800, the legislation now heads to a conference committee, where House and Senate negotiators will need to hash out differences between their respective NDAA drafts. The Senate has its own version moving through the Armed Services Committee, and it's not yet clear whether that chamber's text includes matching psychedelics language. Conference committees can add, strip or rewrite provisions before a final bill goes to the president's desk, so nothing here is locked in until that process wraps up -- typically sometime in the fall, ahead of the new fiscal year.

Extending the Military's Psychedelic Trials to 2033

Photo by RDNE Stock project via Pexels.

Amendment No. 184 does something legislatively simple but practically significant: it swaps the word three for nine everywhere the underlying statute sets a deadline for the Pentagon's psychedelics research program. Instead of expiring after three years, the authority now runs through September 30, 2033. That's a six-year extension on a program that hadn't even finished its first funding cycle.

The program traces back to the fiscal year 2024 NDAA, which President Biden signed with roughly $10 million attached to get it off the ground. That law directed the Department of Defense to open a pathway for active-duty service members diagnosed with PTSD or traumatic brain injury to participate in clinical trials involving psilocybin, MDMA, ibogaine, 5-MeO-DMT and other qualified plant-based compounds. For a population that has historically struggled to access these substances through conventional research channels -- active-duty status usually disqualifies someone from civilian clinical trials -- the program was a narrow but real opening.

Rep. Morgan Luttrell, a Texas Republican and former Navy SEAL, has been the driving force behind this effort since it first appeared in the 2024 defense bill, and he's talked openly about his own experience with psychedelic-assisted therapy after years of combat deployments. His cosponsor list on these amendments crosses party lines in a way that's increasingly rare on drug policy: Republicans Jack Bergman, Derrick Van Orden and Mike Ezell alongside Rulli, paired with Democrats Troy Carter, Morgan McGarvey, Lou Correa, Seth Moulton and Sarah Elfreth. That mix of veterans, combat veterans-turned-lawmakers and members from both parties' health-policy wings has made this one of the few psychedelics measures that hasn't gotten bogged down in the usual partisan drug-war arguments.

Codifying Trump's Executive Order on Psychedelic Medicine

Photo by Werner Pfennig via Pexels.

The second amendment is doing something different and, in some ways, more consequential for how psychedelics research gets treated going forward. Amendment No. 29 takes specific provisions from Executive Order 14401 -- titled Accelerating Medical Treatments for Serious Mental Illness, which Trump signed on April 18, 2026 -- and writes them directly into federal statute. That distinction matters because executive orders can be reversed by the next administration with a single signature, while statutory language survives changes in the White House.

The House Armed Services Committee's report accompanying the bill spells out what comes next. It requires the secretary of defense to submit a formal report by February 1, 2027 assessing the data collected from the ongoing psychedelics trials and laying out what legal and regulatory steps would be needed to expand access beyond the current research population. That's a fairly specific and near-term deadline, and it puts pressure on the Pentagon to actually produce results rather than let the research program run indefinitely without accountability.

The report also has to address how a Right to Try law -- one Trump signed during his first term, aimed at giving terminally ill patients access to experimental treatments outside standard FDA trial pathways -- might intersect with expanded psychedelics access for service members. And it needs to include a proposed timeline for pilot programs or broader research efforts that could launch starting in fiscal year 2027. In other words, Congress isn't just extending the clock on the existing trials; it's asking the Pentagon to start planning for what comes after them.

The IBOGAINE Act and What Got Blocked

Photo by MART PRODUCTION via Pexels.

Riding alongside the NDAA amendments is a standalone bill worth watching in its own right: the IBOGAINE Act, introduced by Reps. Luttrell, Correa, Bergman and McCaul -- largely the same coalition behind the defense bill's psychedelics language. That bill would direct the U.S. attorney general to determine, within 60 days of enactment, whether ibogaine and its related compounds should move from Schedule I to Schedule II under the Controlled Substances Act. A reschedule to Schedule II wouldn't legalize ibogaine outright, but it would formally acknowledge the drug has an accepted medical use and open the door to more conventional research and prescribing pathways, something Schedule I status effectively forecloses.

Not everything psychedelics-adjacent made it through, though. Republican leadership blocked a separate amendment that would have expanded marijuana-testing waivers for military recruits, keeping it off the floor entirely rather than letting it come up for even a voice vote. That's a notable contrast: the same chamber, the same defense bill, and lawmakers were willing to extend psychedelic drug trials to 2033 and codify a presidential order on psilocybin and MDMA, but wouldn't let recruits with a positive cannabis test get a waiver considered.

It points to a real split in how Republican leadership currently views these two categories of drugs, even though both amendments were aimed squarely at helping the same population of service members and recruits. Psychedelics research has found a foothold as a mental-health and veterans-care issue, framed around PTSD and traumatic brain injury recovery. Marijuana, even in the narrow context of recruitment eligibility, still gets treated as a separate and more politically fraught conversation entirely.

What stands out most about this vote isn't the six-year extension or the codification language itself -- it's who signed onto it. A coalition of veterans'-health-focused Republicans like Luttrell, Bergman and Rulli teaming up with Democrats like Correa and Moulton on psychedelics reform suggests this has become one of the rare corners of federal drug policy where cross-aisle cooperation still happens without much friction. That's not nothing, especially in a Congress where most drug policy fights get resolved along predictable party lines.

But the blocked marijuana-testing waiver amendment is the detail that keeps this from reading as some broader thaw in federal drug policy. Lawmakers were comfortable extending psilocybin and MDMA trials for troops already in uniform, while leadership wouldn't even let a vote happen on giving recruits a break for a positive cannabis test. Psychedelics and cannabis are still living in two entirely separate political universes on Capitol Hill, even when the people affected -- service members and the recruits trying to join them -- overlap completely.

Where this all lands depends heavily on what happens in conference with the Senate over the coming months, and readers should keep in mind that none of this changes the legal status of these substances for the general public -- cannabis and psychedelics remain regulated very differently state by state and internationally, so anyone following this issue should check their own jurisdiction's laws rather than assume federal defense policy shifts translate to broader legal change. Even for the troops these amendments are meant to help, actual guaranteed access to psychedelic-assisted therapy isn't happening yet. That waits on the Pentagon's report due February 1, 2027, laying out the legal and regulatory road map for getting there. Until then, this is an extension of research authority and a statutory marker -- not a finished policy.